Suppressive Antibiotic Therapy for Endocarditis

Suppressive Antibiotic Therapy for Prosthetic Valve or Implantable Device Related Infectious Endocarditis

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06107309

Acronym

SATIE

Enrollment

Registered

2023-10-30

Start date

2023-03-01

Completion date

2024-03-31

Last updated

2023-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endocarditis

Keywords

Endocarditis, Antibiotic therapy, Suppressive antibiotics, Long term treatment

Brief summary

Endocarditis are deadly infections, which nowadays occurs mainly among older patients with multiple comorbidities. The incidence is notably high among patients with valvular prosthetic or implantable devices. Management of such situation usually requires intravenous antibiotic therapy along with removal of the infected prosthetic or device. However, such invasive procedures and revision surgeries may be judged unreasonable among these patients, who are then exposed to a high risk of infectious relapse when curative antibiotics are discontinued. In these situation, a long-course antibiotic therapy may be used in order to maintain lasting infection control, to limit the risks of relapse of infection due to the infected device retention, and ultimately to prolong survival. This strategy is already suggested in case of infected prosthesis joint retention (IDSA 2013), and has been proposed for implantable device retention by the American Heart Rhythm Society in 2017, but data regarding its modalities and outcomes are scare. The objectives of this study are to describe the survival of patient under long-term antibiotic therapy for endocarditis, at 6-months and 1 year after initiation. Secondary outcomes includes modalities of the suppressive treatment prescribed, its security (secondary effects, tolerance) and to precise causes of death.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Major subject (≥18 years old) * Subject having benefited from suppressive antibiotic therapy after collegial decision in CPR Endocarditis during the period from January 1, 2016 to January 31, 2023 * Subject not opposing the reuse of their data for the purposes of this research.

Exclusion criteria

* Subject having expressed opposition to participating in the study * Death or loss of sight of the patient before initiation of suppressive antibiotic therapy.

Design outcomes

Primary

Measure	Time frame
Survival of the patient who benefited from suppressive antibiotic therapy	Survival at 6 months, 1 year, 3 years after infection

Countries

France

Contacts

Primary ContactYvon RUCH, MD

yvon.ruch@chru-strasbourg.fr33 3 69 55 12 19

Outcome results